Pharma&Biotech. Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies
|
|
- Marshall Turner
- 6 years ago
- Views:
Transcription
1 Pharma&Biotech Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies Elise-marie R. Beri / Lonza Seng Biologics /, Basel Inc / 10. / IFPAC Mai 2012 Arlington VA / 25 Jan 16
2 Forward-Looking Statements Certain matters discussed in this presentation may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this presentation due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this presentation. 2
3 Abstract There are an increasing number of reports in Biopharma industry Literature touting the numerous advantages of Fully Disposable Biologics Manufacturing Facilities over traditional Stainless Steel Facilities. This talk will review the published studies comparing the Capital and Operating costs of a Fully Disposable Biologics Manufacturing Facility with a Traditional Stainless Steel Manufacturing Facility and outline the approaches that can be taken in order to increase the Competitiveness of Legacy Stainless Steel Facilities. 3
4 Lonza s Global Pharma & Biotech Footprint Portsmouth, NH (2003) Mammalian Cell Culture 3 x 5,000L, 4 x 20,000L cgmp Walkersville Portsmouth Verviers, BE Slough, UK Braine, BE Porriño, SP Slough, UK (1980 s 90 s) Mammalian Cell Culture 200L to 2,000L cgmp SS & SUB Process R&D Services Kouřim, CZ Visp, CH Houston Porriño Spain (2008) Mammalian Cell Culture 4 x 10,000L cgmp Nansha Lonza ,000L of SS Capacity 3 x 1000L SUB (Slough) Singapore Tuas Singapore (2010) Mammalian Cell Culture 200L to 20,000L cgmp Process R&D Services Cell Therapy View our 360 virtual tours at
5 Presentation Overview Key drivers for single use facilities 1990 s Single use (SU) and stainless steel (SS) facilities Advantages and disadvantages Cost of goods comparison 2000 s Optimize legacy SS facility operation 4 x 20K SU facilities: Replacement or complementary 2020 s SU or SS? 5
6 Lonza Press Releases, New manufacturing line to be constructed at Lonza s existing Portsmouth, NH (USA) plant Large-scale, manufacturing line will be operational by the end of 2017 Enables Alexion to add dedicated product supply for 10 years Lonza adds two 1000L single-use bioreactor systems to its current mammalian manufacturing capacity The additional bioreactors will help meet the increasing demand for flexible manufacturing capacity for clinical development supply 6
7 New Facilities Shire's single-use MA plant receives US FDA approval to make VPRIV By Dan Stanton, 18-Feb-2014 Amgen launches $200m biomanufacturing facility in Singapore By Zachary Brennan, 21-Nov-2014 Amgen has completed construction of its first $200m next-gen biomanufacturing facility in Singapore, which is outfitted with single-use technology to allow for greater flexibility. BMS highlights shift to biologics with plans for $900m plant in Ireland By Dan Stanton, 14-Nov-2014 Bristol-Myers Squibb has announced plans to build a biologics facility in Ireland, eight months after winding down a small molecule API plant at the same site Cumbria biopharma plant to create 500 jobs and business ops says GSK By Gareth MacDonald, 12-Feb-2014 GSK has unveiled designs for the 350m ($587m) biomanufacturing plant it intends to build in UK and confirmed that construction will start early next year Source: 7
8 Titer Range, g/l Market Trends Trend is towards lower volume products and higher titers High Low Year Source: CMO Biologics: Market, Competition and Strategy, Lonza, October 2013 High titers and lower annual demand Biosimilars in this category due to market fragmentation Lower production bioreactor size can meet anticipated annual demand for multiple future products 8
9 Technology Trends Increasing availability of Single Use Technologies Single use bioreactors Single use mixers Pre-packed columns All technologies are shown for illustrative purposes Membrane adsorbers Bioprocess bags and containers Disposable systems for VI, VRF, TFF Images provided courtesy of EMD Millipore Corporation and GE LifeSciences 9
10 SUT Facilities Advantages Disadvantages Lower CAPEX & footprint More parts to manage Lower build time Reduced validation effort Possibility of scaleout Increased amount of solid waste Lower degree of automation Lower fixed costs & OPEX Cannot exploit economy of scale No CIP / SIP Reduced maintenance Reduced change over Lower utility usage Other Increased flexibility Less complex to operate Additional Reference: Aspen Brook Consulting, 7 th Annual Single Use Market Survey 10
11 Let the $$$$ Speak Howard Levine ( Capital cost Cost per gram SU (2K) vs SS (2K) SU facility ~ 25% lower SU facility ~ 19% lower COGS Andrew Sinclair ( Integrated_Final_V02.pdf) SU (2K) vs SS (2K) SU (2K) vs SS (15K)* Cost per gram SU facility ~ 21% lower SS facility ~ 49% lower * Multiple products with moderate annual demand at 15K with 100% utilization Modeling indicates 2K SU facility is cost competitive with SS at 2K However SS (15K) offers significant economy of scale 11
12 Legacy SS Facilities Advantages Disadvantages Fully or partially depreciated High fixed costs Large scale equipment Designed for lower titer range Economy of scale Old or obsolete technologies Less consumables compared to SU Introducing new technologies is a higher burden Operational experience More amenable for automation Multi-products / Majority commercially approved Increasing Efficiency of Legacy SS Facilities is NECESSARY 12
13 Legacy SS plants - Opportunities Operational Excellence Increase facility capability Implement innovative technologies Paperless, automation, Robotics All technologies are shown for illustrative purposes 13
14 # Batches Increase Facility Capability Handle higher titers Seed bioreactors as production bioreactors Higher product volumes in DSP Jeff Robinson, Lonza, IBC, 2011 Integrating disposable mixing systems Campaign durations Number Batches per Year Reduce facility bottlenecks +25% Optimize product mix & campaign length +15% at each site Reduce changeover (CO) time, # changeovers CO time (+ Debottlenecking) 14
15 Next Generation Technologies There are many new technologies There are many new technologies!!! Prioritize! Prioritize!! Prioritize!!! 15
16 Prioritization System Economic value Net return / cost of implementation Higher the ratio, higher the score Batch Cost Drivers Impact Replacing obsolete technologies Improving process yield Facility Time Direct Labor Raw Materials (ex Resins) Changeover Other Ease of implementation Like for like Regulatory changes 16
17 Harmonized and Simplified Technology Evaluation & Implementation Process Idea Planning Feasibility Proof of Concept Development Qualification & Validation Implementation Extension 17
18 Implementation of Laboratory Execution System (LES) Increasing use of automation and data integration tools in process development, manufacturing, and QC. ERP Systems, Document Management Systems, LIMS PD Manufacturing QC ELN ebr LES Lab Instruments, DCS, Lab Software 18
19 Real Time Process Monitoring, Reporting, Analysis And Control CURRENT STATE FUTURE STATE Offline data analysis SPC, MVA, modeling,. Retrospective Prevent future issues FUTURE VISION Real time monitoring Inline probes, SPC, MVA, modeling, dashboards Prospective Prevent current issues Improve future production Dashboards BENEFITS Increased process Knowledge Online advisory Online control Improved operations Intelligent Manufacturing 19
20 Summary Multiple efforts across Lonza Debottlenecking Throughput improvement Operational excellence Next generation technologies Automation Combined efforts synergistic benefits Increase competitiveness of legacy SS facilities New Facilities, SU 66,000 L SU Facilities High titer products with low annual demand Clinical Production 590,000 L SS is 9x SUT 20
21 Acknowledgements Jeff O Connor Trent Johnson Michael Moedler Joanna Ferrero Jessica Jean Diego Schmidhalter Una de Wit Henriette Schneider Maribeth Janke 21
A CMO s View on Platform Technologies
Pharma&Biotech A CMO s View on Platform Technologies A3P BioProduction 2013 BioPurification, Lyon, France Louise Elise-marie Ingram/ Seng Lonza /, Basel Biologics / 10. Mai / 182012 Jun 13 Disclaimer Certain
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationFacility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study
24 th Interphex, Japan, Technical conference June 29 th, 2011 Michael Brown Facility construction and start up for commercial scale manufacturing of monoclonal antibodies - a case study Lonza overview
More informationKelly Thom Associate Principal Scientist Fujifilm Diosynth Biotechnologies. Your Biologics and Vaccines CDMO Partner of Choice.
Process Design for an All Single-Use Manufacturing Facility: Scaling Low to High Titer Processes to Fit Standard mab Equipment BioProcess International West March 2, 2017 Kelly Thom Associate Principal
More informationOur passion is to deliver sustainable value to our customers 2008 First Half Results 23 July 2008
Our passion is to deliver sustainable value to our customers 2008 First Half Results 23 July 2008 Stefan Borgas Chief Executive Officer Disclaimer Certain matters discussed in this presentation may constitute
More informationPharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful
Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and
More informationCurrent Trends in Single Use Technologies: Future Developments Affecting Production
5 September 2016 Current Trends in Single Use Technologies: Future Developments Affecting Production Eric S. Langer President and Managing Partner, BioPlan Associates, Inc. 2275 Research Blvd, Suite 500
More informationFuture biologics manufacturing
Future biologics manufacturing Process integration with single-use technology Dr. Günter Jagschies Senior Director, Strategic Customer Relations GE Healthcare Life Sciences Uppsala, Sweden Mammalian Cell
More informationBusiness Update: First Quarter 2007
Conference Call, April 19 th, 2007 Business Update: First Quarter 2007 Stefan Borgas, CEO Disclaimer Certain matters discussed in this presentation may constitute forwardlooking statements. These statements
More informationEnhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies. 06 February 2018
Enhancing Upstream and Downstream Process Methods Through Implementation of Single-Use Technologies 06 February 2018 Overview Single-use technology (SUT) is a rapidly evolving technology that focuses on
More informationWe work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Full Year Results 27 January 2009 Stefan Borgas Chief Executive Officer Disclaimer
More informationSingle-use technology and sustainability: quantifying the environmental impact
Single-use technology and sustainability: quantifying the environmental impact Bill Flanagan Director, Ecoassessment Center of Excellence, GE 1 November 2016 Imagination at work Agenda Biopharmaceutical
More informationEconomic Impact of Single-Use Bioreactors
Economic Impact of Single-Use Bioreactors Rick Stock 2012 BIO International Convention BioProcess Theater Presentation Upstream Processing Boston, MA June 19th, 2012 BioProcess Technology Consultants www.bptc.com
More informationLONZA Q1 QUALITATIVE BUSINESS UPDATE 2019
LONZA Q1 QUALITATIVE BUSINESS UPDATE 2019 Contents Lonza Q1 2019 Corporate Overview Lonza Q1 2019 Segments Overview - Pharma Biotech and Nutrition - Specialty Ingredients Outlook 2019 and Mid-Term Guidance
More informationWe work with passion, using advanced technologies, to transform life science into new possibilities for our customers
We work with passion, using advanced technologies, to transform life science into new possibilities for our customers Business Update: First Quarter 2009 23 April 2009 Stefan Borgas Chief Executive Officer
More informationOur passion is to deliver sustainable value to our customers Business Update: Third Quarter October 2007
Our passion is to deliver sustainable value to our customers Business Update: Third Quarter 23 October Stefan Borgas Chief Executive Officer Disclaimer Certain matters discussed in this presentation may
More informationTowards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned
Case studies in process intensification Towards Flexible Single-use Biomanufacturing: Key Technologies Needed and Lessons Learned March 14, 2017 San Diego, California Adam Goldstein, Oliver Molina, Michelle
More informationRecent Developments & Future Directions in the Production of Monoclonal Antibodies. Rob Noel Plasma Product Biotechnology Conference 2009, Menorca
Recent Developments & Future Directions in the Production of Monoclonal Antibodies Rob Noel Plasma Product Biotechnology Conference 2009, Menorca Forecast sales by molecule type ($m), 2006 12 600,000 Pharmaceuticals
More informationIndustry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
Global Biomanufacturing Trends, Capacity and Technology Drivers Industry Biomanufacturing Capacity Overview Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. DCAT March 14 17, 2016
More informationSingle-use Market Growth: Trends Accelerating Single-use Adoption
Single-use Market Growth: Trends Accelerating Single-use Adoption Eric S. Langer President and Managing Partner BioPlan Associates, Inc. 2275 Research Blvd, Suite 500 Rockville, MD 20850 301-921-5979 www.bioplanassociates.com
More informationCost impact analysis to inform the process development plan, clinical trial program and business planning
Cost impact analysis to inform the process development plan, clinical trial program and business planning Compare a future-state model to the current as is process Intro to exmoor Biomanufacturing technical
More informationBioprocessing Challenges: High-Titer Mammalian-Based Cell Systems. Elements influencing the way Biologics may be manufactured /supplied in the future
Bioprocessing Challenges: High-Titer Mammalian-Based Cell Systems Jonathan Romero CMC Leadership, Technical Development Pharmaceutical Operations & Technology 2015 ISPE PRODUCT SHOW Business Drivers Elements
More informationQ Qualitative Business Update Mid-Term Guidance Until End 2018
Pharma&Biotech Corporate Q1 2015 Qualitative Business Update Mid-Term Guidance Until End 2018 Richard Ridinger CEO Richard Ridinger / Lonza Group Ltd, Basel / 28 April 2015 Lonza Overview Q1 2015 Qualitative
More informationStainless steel or plastic? The Rentschler decision process
Stainless steel or plastic? The Rentschler decision process BPI West, March 1, 2017 Content 1 Introduction 2 Cost 3 Scale 4 Safety 5 Outlook BPI West, San Francisco February/March 2017 2 Location of the
More informationThe ebioplant. Implementation of an Integrated MES-DCS solution in a new biotech plant. 10 th April 2014
The ebioplant Implementation of an Integrated MES-DCS solution in a new biotech plant 10 th April 2014 Agenda 2 ן UCB UCB at a Glance Focus on Cimzia ן The Edelweiss Project Project Objective Process Description
More informationLonza Capital Markets Day Staying Ahead. Marc Funk COO Lonza Pharma & Biotech. Capital Markets Day September 2018
Corporate Lonza Capital Markets Day 2018 Staying Ahead Marc Funk COO Lonza Pharma & Biotech Staying Ahead Lonza Capital Markets Day 2018 Agenda Outlook Lonza Pharma & Biotech overview Delivering on our
More informationIntensification of a Perfusion Platform using Single-use XCell ATF Systems
Intensification of a Perfusion Platform using Single-use XCell ATF Systems Olaf Mol Sr. Bioprocess Scientist The world leader in serving science Global Footprint- Biologics Princeton, USA PD Center of
More informationClare Simpson 21 st November Content courtesy of Steve Jones, Paul Illot, Bert Frohlich, Thomas Ryll Biopharm Services
Modelling a technology roadmap for acceleration of global industry innovation Presentation to Wales Life Science Hub, Health Economics Special Interest Group Clare Simpson 21 st November 2016 Content courtesy
More informationThe Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics
The Braine BioPilot An Integral Part of Bioprocess Development for Cell Culture- Based Biologics Visit of Alabama Biotech Oct 2014 Alain BERNARD Vice President GPS, UCB Technical Operations Tech Ops BioTech
More informationTable of Contents. Presented by
Table of Contents Presented by HighTech Business Decisions 3150 Almaden Expressway, Suite 222, San Jose, CA 95118 Tel: (408) 978-1035 Fax: (408) 978-8925 www.hightechdecisions.com May 2017 TABLE OF CONTENTS
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationProcess economic simulation for scalable production of adenovirus
Process economic simulation for scalable production of adenovirus This application note discloses process economic modelling of a modern start-to-finish adenovirus production process. The novel process
More informationBrazil: A Global Biotech Hub
Brazil: A Global Biotech Hub Single Use Devices Enables Bioprocessing for Domestic Biologics, Biosimilars, Export Mathew Cherian Ph.D. Director Pharmaceutical Development Hospira, Inc. USA Brazil s Potential
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationKey Success Factors for Bioprocess Technology Selection, Scale-up & Engineering of New Facilities
Key Success Factors for Bioprocess Technology Selection, Scale-up & Engineering of New Facilities by Edi D. Eliezer Principal BioPrizM www.bioprizm.com (856) 904.2428 Key Factors for Bioprocess Technology
More informationImproving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns
Improving Downstream Manufacturing Productivity with Pre-Packed Chromatography Columns Michael Dittmer MedImmune, BioProcess Engineering BPI West, San Francisco, CA March 2 nd, 2017 Outline Motivation
More informationAssessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development
Assessing and Managing Strategic Risk for Next Generation Processes of Established Brands Eric R. Garr Associate Director, Global Product Development and Supply Our Mission To discover, develop and deliver
More informationFast Trak Services from molecule to market
GE Healthcare Fast Trak Services from molecule to market OPEN At the speed of Fast Trak Whether you re looking to launch a new molecule, enhance existing capacity, or bring biosimilars to emerging markets,
More informationContinuous Processing Progress in Manufacturing
Cell World Conference, San Francisco, May 25-26 2017 Dr. Berthold Boedeker, Bayer AG, Biological Development Biologics at Bayer Regulatory support / drivers aof continuous processing Bayer s approach to
More informationImproving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns By K. John Morrow, Jr. Ph.D. In the last two decades, the bioprocessing industry has confronted the demands
More informationTransforming Lonza Specialty Ingredients into a Modern Chemicals Business
Capital Markets Day Transforming Lonza Specialty Ingredients into a Modern Chemicals Business Increasing Market Focus Towards the Healthcare Continuum Sven Abend, COO Specialty Ingredients Capital Markets
More informationBIOPHARMACEUTICAL MANUFACTURING CONFERENCE
BIOPHARMACEUTICAL MANUFACTURING CONFERENCE Bob Bader Sr. Manager Technology, Jacobs December 4 th 2017 MULTI PRODUCT MADNESS FLEXIBLE MANUFACTURING FACILITY CASE STUDY AMGEN MOF 1 ASM Next Generation Manufacturing
More informationTransition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics
A Virtual Think Tank Executive Summary Transition to Next Gen Downstream Processing to Capitalize on Growth Opportunities in High-Value Low-Volume Biologics By: Unmesh Lal, Program Manager, Transformational
More informationEuropean Biopharmaceutical Review October 2010 (Pub date January 2011) Eric S. Langer
European Biopharmaceutical Review October 2010 (Pub date January 2011) Eric S. Langer European Biomanufacturing Efficiency Outstripping US Outlook for Capacity Utilisation Through 2015 Introduction European
More informationLeading Supplier to the Life Science Industry
Leading Supplier to the Life Science Industry 2011 Full Year Results 25 January 2012 Rolf Soiron (Chairman) and Management Committee Forward-looking Statements Certain matters discussed in this presentation
More informationThe Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes
The Power of Data to Accelerate Development of Robust & Scalable Manufacturing Processes Susan Abu-Absi Director, Manufacturing Sciences & Technology Bristol-Myers Squibb Devens, MA USA May 11, 2016 1
More informationNew technologies in biopharmaceutical processes BioTech Vaccines Plasma
New technologies in biopharmaceutical processes BioTech Vaccines Plasma Dominik Arnold dominik_arnold@pall.com Challenges in Down Stream Processing Higher. Titers >4 g/l Yield > 90% Protein concentration
More informationSINGLE USE SYSTEMS IN NEXT-GEN BIOLOGICS DRUG SUBSTANCE MANUFACTURING
JUNE 21, 2018 SINGLE USE SYSTEMS IN NEXT-GEN BIOLOGICS DRUG SUBSTANCE MANUFACTURING GANESH VEDANTHAM PROCESS DEVELOPMENT MODALITIES IN THE AMGEN PORTFOLIO 2 AMGEN IS EVOLVING OPERATIONS CAPABILITIES TO
More informationApplication of Disposable Technologies in Biopharmaceutical Manufacturing
BMD Summit, Disposables for Biopharm Production 13th December 2005 Reston, VA, USA Application of Disposable Technologies in Biopharmaceutical Manufacturing Martin Wrankmore, Continuous Improvement Lead,
More informationDisposable Technology - a technobusiness perspective
Disposable Technology - a technobusiness perspective A Business Briefing being held on 10th March 2011 With Mrs Miriam Monge, VP Marketing Biopharm Services, Chairs: Prof Gary Lye and Prof Eli Keshavarz-Moore,
More informationSEEING THE FUTURE A REVIEW OF THE ISPE 2016 FACILITY OF THE FUTURE CONFERENCE. Phil McDuff VP Global Engineering Biogen
SEEING THE FUTURE A REVIEW OF THE ISPE 2016 FACILITY OF THE FUTURE CONFERENCE Phil McDuff VP Global Engineering Biogen Robert Chew President & CEO Commissioning Agents Inc. Jim McGlade Client Leader BHDP
More informationSingle Use Bioreactor Scale up: Introduction of a 2000L SUB Equipment Train in 12 months
Single Use Bioreactor Scale up: Introduction of a 2000L SUB Equipment Train in 12 months Finesse CellWorld San Fransisco Claire Walsh BSc, MSc BioProcess Skills and Technology, Operations, Janssen Sciences
More informationEvaluating facility design and capacity planning decisions for clinical and commercial supply with hybrid continuous processes
Engineering Conferences International ECI Digital Archives Integrated Continuous Biomanufacturing II Proceedings Fall 11-2-2015 Evaluating facility design and capacity planning decisions for clinical and
More informationEvolve with flexibility
GE Healthcare Evolve with flexibility Single-use bioprocessing Biomanufacturing: an evolving industry The biopharmaceuticals landscape is undergoing unprecedented change. As more and more biologics go
More informationQ Qualitative Business Update. Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers
Corporate Q1 2018 Qualitative Business Update Lonza Reports Positive Start to 2018 with Businesses Along the Healthcare Continuum as Growth Drivers Richard Ridinger CEO Additional Information and Disclaimer
More informationSingle-use technology in downstream unit operations
Single-use technology in downstream unit operations ÄKTA ready chromatography system and more Madhu Raghunathan, Bioprocess capability days, Boston Imagination at work Presentation outline Introduction
More informationCase Study Lonza: Manufacturing of Antibody Drug Conjugates using Single Use Equipment Frankfurt 8. November 2018
Case Study Lonza: Manufacturing of Antibody Drug Conjugates using Single Use Equipment Frankfurt 8. November 2018 Lonza Pharma & Biotech Fabian Studer 2018 Disclaimer The information contained herein are
More informationGOING PAPERLESS FROM LAB TO PLANT
TECHNOLOGY BRIEF GOING PAPERLESS FROM LAB TO PLANT Capturing and harmonizing data in product R&D and manufacturing/quality facilities to improve Operational Excellence THE CHANGING ROLE OF INFORMATICS
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationDeveloping a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods
Developing a Best Practice Guide for Leachables Risk Assessment, Study Design, and Analytical Methods Single-use systems (SUS) offer biopharmaceutical manufacturers significant gains in process flexibility,
More information25 Years of Biopharma Industry Growth What a difference a quarter century makes
Issue Date: June 2012 BP Special 25 th Anniversary 2000 words (Actual 2680) BioPharm International Editor Contact: Angie Drakulish, Sr. Managing Editor, adrakulich@advanstar.com Description: Retrospective
More informationFast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China
GE Healthcare Fast Trak Services: Ongoing collaboration aims to accelerate biosimilar approval in China A case study Fast Trak Services Ongoing collaboration aims to accelerate biosimilar approval in China
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationCorporate Presentation
Presentation July 2018 2018 Closer Than You Think 2018 2 Table of Contents Lonza at a Glance Full-Year Results 2017, Outlook 2018 and Mid-Term Guidance 2022 Deep-Dive into Segments Pharma & Biotech Specialty
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationThe Influence of Scale of Operation on Purification Process Design
The Influence of Scale of Operation on Purification Process Design Jim Davies, Martin Smith, Julian Bonnerjea Dr Jim Davies Biochemical Engineer Lonza Biologics Slough UK Introduction Product Requirement
More informationInspiring Advances in Bioprocessing. John Bonham-Carter March 14, 2017
Inspiring Advances in Bioprocessing John Bonham-Carter March 14, 2017 Bioprocessing Trends Emerging trends, new challenges Integrated continuous processing Upstream continuous processing (perfusion) proven
More informationBIOTECH AUTOMATION THE PAST, PRESENT AND FUTURE
BIOTECH AUTOMATION THE PAST, PRESENT AND FUTURE Rick Pierro Superior Controls January 18th, 2018 Biotech Automation - The Past, Present and Future. Automation in Biotech History (PLC s and DCS s) Advances
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationKeeping up with Single-Use Geoffrey Hodge SVP Operations Unum Therapeutics 07 Oct 15
Keeping up with Single-Use Geoffrey Hodge SVP Operations Unum Therapeutics 07 Oct 15 Outline Introduction / Overview Technology Survey Economics Quality Single Use Facilities Summary 1 Introduction Disclaimer
More informationABL Europe s GMP manufacturing facility for viral vector production
ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures
More informationCalendar. The Clear Solution to Reach the Global Biopharma Audience. INTERNATIONAL
The Clear Solution to Reach the Global Biopharma Audience yvdavyd/getty Images & blackred/e+/getty Images 2017 EDITOrial Calendar Editorial Coverage Special Themed Issues January Biopharma Outlook for
More informationCSL s Large Scale Cell Culture Facility
BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL Objective How to maximise the opportunity to build a state-of-theart facility
More informationContinuously Improving Bioprocesses: Biopharmaceutical Capabilities
Continuously Improving Bioprocesses: Biopharmaceutical Capabilities Pall Corporation A Legacy of Innovation Dr. David B. Pall Founded by Dr. David B. Pall in 1946, Pall Corporation has grown from a company
More informationFast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing
GE Healthcare Fast Trak Services: Long-term collaboration supports speed to market in single-use biomanufacturing A case study Fast Trak Services Long-term collaboration supports speed to market in single-use
More informationInnovation, Production, and Sustainable Job Creation: Reviving U.S. Prosperity
Innovation, Production, and Sustainable Job Creation: Reviving U.S. Prosperity Technology, Policy and Product Life Cycle: The Evolving Geography of Biomanufacturing Elisabeth B. Reynolds From the MIT Industrial
More informationA Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody.
A Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody. Jeremy M Tong (presenting), Mark S Kettel, Edward M Perry, David J Pain, David M Valentine,
More informationProduct Quality beyond Compliance Case Study: Continuous Manufacturing
Product Quality beyond Compliance Case Study: Continuous Manufacturing IFPAC Conference, Washington D.C. Yanxi Tan Cain, Ph.D. Regional Head Novartis Pharma Quality Operation January 27th, 2015 Disclaimer
More informationBiosimilars Manufacturing- Cost reduction vitalities
Biosimilars Manufacturing- Cost reduction vitalities The Biopharmaceutical industry has emancipated a surge of growth over the past 20 years, primarily, due to blockbuster launches of novel biologics and
More informationBiopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference
Biopharmaceutical Multi-Product Facilities: the Challenges and the Solutions. Frank Hallinan EBE Biopharmaceutical Manufacturing & CMC Conference Barcelona, March 21, 2011 Agenda: The Past The Business
More informationDisposables Technology Trends, drivers & practices. Gordon Farquharson July 2017
Disposables Technology Trends, drivers & practices Gordon Farquharson July 2017 Agenda 1. Business drivers 2. Technical trends 3. Systems in practice 4. Comparison with fixed systems & justifications Slide
More informationThe Changing Landscape of Mammalian Cell Culture Manufacturing Capacity
The Changing Landscape of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual bioprocessuk Conference Nov 30-Dec 1 2011 Glasgow, Scotland BioProcess Technology Consultants
More informationProduct lifecycle management in one site
Product lifecycle management in one site Today s world provides multiple opportunities for a biopharma company. An aging global population and the prevalence of chronic and communicable diseases are creating
More informationTechnology and Innovation are driving change in the pharmaceutical industry Stefan Krauß Business Segment Pharmaceuticals, Siemens AG
Technology and Innovation are driving change in the pharmaceutical industry Stefan Krauß Business Segment Pharmaceuticals, Siemens AG Realize innovation. Page 1 MindSphere + Video Digitalization changes
More informationApplication of Single-Use Equipment for Buffer Storage and Distribution in Medium Size mab Production Facility
Reprinted from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE JANUARY/FEBRUARY 2014, VOL 34, NO 1 Copyright ISPE 2014 www.pharmaceuticalengineering.org facilities and equipment Application
More informationMulti-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities
Multi-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities Dr.-Ing. Kathleen Mihlbachler, LEWA Bioprocess Repligen Seminar: Advances in Bioprocessing,
More informationThe Continuous Way. Why take the continuous route? Because it leads to better, faster bioprocessing. A Sponsored Supplement From
The Continuous Way Why take the continuous route? Because it leads to better, faster bioprocessing. A Sponsored Supplement From www.pall.com/biotech Meet the Experts Marc Bisschops Director SLS, Continuous
More informationWelcome! CellWorld 2017 San Francisco, CA USA
Welcome! CellWorld 2017 San Francisco, CA USA Intensity Innovation Involvement Integrity Company (Business Unit) Overview Name: Finesse HQ: Santa Clara, CA Founded: 2005 Employees: ~150 Business Description
More informationLonza Nansha, China For Global Excellence in Advanced Chemical Synthesis
Pharma&Biotech Lonza Nansha, China For Global Excellence in Advanced Chemical Synthesis Lonza Guangzhou Nansha Ltd «Twenty-five years ago Lonza built one of the world s most advanced cgmp chemical manufacturing
More informationEffect of Biosimilar Development on Global Manufacturing Capacity
Effect of Biosimilar Development on Global Manufacturing Capacity Patti Seymour Senior Consultant BioProcess Technology Consultants, Inc. IBC Life Science s Biopharmaceutical Development and Production
More informationWHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES
WHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES John Coyne Sr. Manager: Bioprocessing Research and Development Manufacturing Pfizer, Inc. 23 Years Industry Experience,
More informationAccelrys ROTH Growth Stock Conference
Accelrys ROTH Growth Stock Conference Feb. 20, 2008 Presented by: Mark Emkjer, CEO Rick Russo, CFO Forward-looking Statements When used in this presentation, words such as expects, believes, anticipates,
More informationChallenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies
Challenges in the cgmp Manufacturing of hescs: Lessons Learned from Monoclonal Antibodies ISCT 2011 Annual Meeting Rotterdam, The Netherlands May 18 21, 2011 BioProcess Technology Consultants www.bptc.com
More informationContinuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities
Continuous Biomanufacturing: Relevant Experiences with Development, Hybrid Implementation, and Emerging Opportunities Erik Fouts, Ph.D. VP and Site Head, Novato Operations 3-4 December ASTM E2968 14 Continuous
More informationPerfusion and Beyond The XCell TM ATF System
Perfusion and Beyond The XCell TM ATF System Earl Pineda Field Application Scientist Web ads May 9, 2018 Inspiring advances in bioprocessing since 1985 Repligen Corporation: one of the fastest-growing
More informationGE Healthcare. Process economy and production capacity using single-use versus stainless steel fermentation equipment
GE Healthcare Process economy and production capacity using single-use versus stainless steel fermentation equipment Process economic comparison between fermentation in single-use versus stainless steel
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationspeeding medicines to people Potential Benefits of PAT for Biomanufacturing IFPAC 2005
speeding medicines to people Potential Benefits of PAT for Biomanufacturing IFPAC 2005 Outline PAT for Biologics (Biotherapeutics) Mfg. What is a biotherapeutic? Converging trends in Biotech PAT player
More information